

Mouse anti-Human TIM-3/HAVCR2/CD366 Monoclonal Antibody | anti-TIM-3/HAVCR2/CD366 antibody

TIM-3/HAVCR2/CD366 (BSB-163)

CATALOG # AAA59395	HOST Mouse	REACTIVITY Human
------------------------------	----------------------	----------------------------


PRODUCT SYNONYMS

TIM-3/HAVCR2/CD366; Monoclonal Antibody; TIM-3/HAVCR2/CD366 (BSB-163); tim-3. tim3; anti-tim-3; anti-tim3; HAVCR2; anti-HAVCR2; CD366; anti-CD366; anti havcr2; anti cd366; anti-TIM-3/HAVCR2/CD366 antibody

PRODUCT SPECIFICATIONS

Host	Mouse
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2c
Clone Number	BSB-163
Form/Format	Paraffin, Frozen TIM-3 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
Immunogen	Recombinant extracellular domain of the human TIM3 protein.
Control	Colon, Testis, Tonsil, Liver
Localization	Cytoplasmic
Preparation and Storage	Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

IMAGES



IHC (Immunohistochemistry)

TIM-3 Antibody Immunohistochemistry on an FFPE Ductal Breast Carcinoma Tissue

Antibody Type	Dilution	Volume/QTY
Prediluted	Ready-To-Use	3.0 ml
Prediluted	Ready-To-Use	7.0 ml
Prediluted	Ready-To-Use	15.0 ml
Concentrated	1:25-1:100	0.1 ml
Concentrated	1:25-1:100	0.5 ml
Concentrated	1:25-1:100	1.0 ml
Control Slides		5

Dilution Info

ADDITIONAL INFORMATION

Related Product Information for anti-TIM-3/HAVCR2/CD366 antibody	T-cell Immunoglobulin and Mucin-domain Containing-3 (TIM-3), also known as Hepatitis A virus cellular receptor 2 (HAVCR2), is a protein that in humans is encoded by the HAVCR2 gene. TIM-3 is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate CD8+ T-cell exhaustion. TIM-3 expression is up-regulated in tumor-infiltrating lymphocytes in Lung, Gastric, Head & Neck Cancers, Schwannoma, Melanoma and Follicular B-cell Non-Hodgkin Lymphoma. The TIM-3 pathway may interact with the PD-1 pathway in the dysfunctional CD8+ T cells and Tregs in cancer. TIM-3 is mainly expressed on activated CD8+ T cells and suppresses macrophage activation following PD-1 inhibition. Upregulation has been observed in tumors progressing after anti-PD-1 therapy. It has been reported that early breast cancer patients with TIM-3+ iTILs have significantly improved breast cancer-specific survival whereas TIM-3+ sTILs did not reach statistical significance and it was concluded that the presence of TIM-3+ iTILs is an independent favorable prognostic factor in the whole cohort as well as among ER negative patients. In myelogenous leukemia (AML), upregulated TIM-3 during AML could reduce cytokine production. Co-expression of PD-1 and TIM-3 was correlated with AML progression. In follicular B-cell non-Hodgkin lymphoma, TIM-3 was expressed on nearly 35% of lymph node CD4+ and CD8+ T cells and could mediate T-cells exhaustion. In glioma patients, TIM-3 was correlated with cancer immune escape and might be a potent target. In colorectal cancer, upregulation of TIM-3 could restrict T-cell responses and might participate in tumorigenesis. The expression of TIM-3 antibody might be an independent prognostic factor for colorectal cancer.
--	--

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/monoclonal/tim-3-havcr2-cd366-antibody-clone-bsb-163-elisa/59395>